Immunome (NASDAQ:IMNM – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Risk & Volatility
Immunome has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
Earnings and Valuation
This table compares Immunome and Viridian Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunome | $6.94 million | 359.17 | -$212.39 million | ($2.38) | -9.25 |
| Viridian Therapeutics | $70.85 million | 28.02 | -$342.60 million | ($3.32) | -5.80 |
Immunome has higher earnings, but lower revenue than Viridian Therapeutics. Immunome is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Immunome and Viridian Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunome | 1 | 0 | 13 | 0 | 2.86 |
| Viridian Therapeutics | 1 | 0 | 13 | 0 | 2.86 |
Immunome presently has a consensus target price of $33.17, suggesting a potential upside of 50.69%. Viridian Therapeutics has a consensus target price of $38.79, suggesting a potential upside of 101.38%. Given Viridian Therapeutics’ higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Immunome.
Insider & Institutional Ownership
44.6% of Immunome shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Immunome and Viridian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunome | N/A | -51.15% | -47.32% |
| Viridian Therapeutics | -490.31% | -80.19% | -48.84% |
Summary
Immunome beats Viridian Therapeutics on 9 of the 12 factors compared between the two stocks.
About Immunome
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
About Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
